NPI 1801187489: Open Payments
NPI 1801187489. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$409 in 20 payments from 10 companies in 2025. Trend: 2023 $523 · 2024 $430 · 2025 $409
Food & beverage: $409
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $149 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| Lilly USA, LLC | 2 | $42 |
| Abbott Laboratories | 2 | $41 |
| ABBVIE INC. | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Exact Sciences Corporation | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
Products named: Wegovy, Ozempic, AIRSUPRA, JARDIANCE, Rybelsus, UBRELVY, Auvelity, Cologuard Collection Kit.
